Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBIZUR all-case post-marketing surveillance in acquired hemophilia A
jRCT2031240148Recruiting
- Sponsor
- Takeda
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of susoctocog alfa in acquired haemophilia (AH), sponsored by Takeda. Primary endpoints: Number of participants who experience at least one treatment-emergent adverse event and Number of participants who experience at least one adverse drug reaction. Started Jun 2024; status: recruiting.
02
Drugs
susoctocog alfa
03
Conditions
acquired haemophilia (AH)
Beyond the preview
Go deeper on jRCT2031240148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240148.